The Sigma-1 Receptor As Key Common Factor in Cocaine and Food-Seeking Behaviors
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(125I)Iodoazidococaine, a Photoaffinity Label for the Haloperidol-Sensitive Sigma Receptor (Cocaine/[3H]Cocaine Binding/Cocaine-Binding Protein) JOHN R
Proc. Natl. Acad. Sci. USA Vol. 89, pp. 1393-1397, February 1992 Biochemistry (125I)Iodoazidococaine, a photoaffinity label for the haloperidol-sensitive sigma receptor (cocaine/[3H]cocaine binding/cocaine-binding protein) JOHN R. KAHOUN AND ARNOLD E. RuOHO* Department of Pharmacology, University of Wisconsin Medical School, Madison, WI 53706 Communicated by James A. Miller, October 8, 1991 (received for review July 10, 1991) ABSTRACT A carrier-free radioiodinated cocaine photo- cifically block the photolabeling ofthe DA transporter, it was affinity label, (-)-3-('25I)iodo-4-azidococaine [('25I)IACoc], not established whether cocaine bound directly to this protein has been synthesized and used as a probe for cocaine-binding or to an associated protein. Recently, the human NE trans- proteins. Photoaffinity labeling with 0.5 nM ('25I)IACoc re- porter has been expression-cloned as cDNA and overex- sulted in selective derivatization of a 26-kDa polypeptide with pressed in HeLa cells (13). The ability of cocaine to block the pharmacology of a sigma receptor in membranes derived [3H]NE uptake into these HeLa cells provides good evidence from whole rat brain, rat liver, and human placenta. Covalent that cocaine binds directly with this transporter. labeling of the 26-kDa polypeptide was inhibited by 1 FM Although cocaine has been shown to block the binding of haloperidol, di(2-tolyl)guanidine (DTG), 3-(3-hydroxyphenyl)- sigma ligands to rat and guinea pig brain membranes with N-(1-propyl)piperidine (3-PPP), dextromethorphan, and car- relatively low affinity, the nature and physiological impor- betapentane. Stereoselective protection of (125I)IACoc photo- tance of this interaction is not known. -
The Pharmacologist 2 0 0 6 December
Vol. 48 Number 4 The Pharmacologist 2 0 0 6 December 2006 YEAR IN REVIEW The Presidential Torch is passed from James E. Experimental Biology 2006 in San Francisco Barrett to Elaine Sanders-Bush ASPET Members attend the 15th World Congress in China Young Scientists at EB 2006 ASPET Awards Winners at EB 2006 Inside this Issue: ASPET Election Online EB ’07 Program Grid Neuropharmacology Division Mixer at SFN 2006 New England Chapter Meeting Summary SEPS Meeting Summary and Abstracts MAPS Meeting Summary and Abstracts Call for Late-Breaking Abstracts for EB‘07 A Publication of the American Society for 121 Pharmacology and Experimental Therapeutics - ASPET Volume 48 Number 4, 2006 The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. The Editor PHARMACOLOGIST Suzie Thompson EDITORIAL ADVISORY BOARD Bryan F. Cox, Ph.D. News Ronald N. Hines, Ph.D. Terrence J. Monks, Ph.D. 2006 Year in Review page 123 COUNCIL . President Contributors for 2006 . page 124 Elaine Sanders-Bush, Ph.D. Election 2007 . President-Elect page 126 Kenneth P. Minneman, Ph.D. EB 2007 Program Grid . page 130 Past President James E. Barrett, Ph.D. Features Secretary/Treasurer Lynn Wecker, Ph.D. Secretary/Treasurer-Elect Journals . Annette E. Fleckenstein, Ph.D. page 132 Past Secretary/Treasurer Public Affairs & Government Relations . page 134 Patricia K. Sonsalla, Ph.D. Division News Councilors Bryan F. Cox, Ph.D. Division for Neuropharmacology . page 136 Ronald N. Hines, Ph.D. Centennial Update . Terrence J. Monks, Ph.D. page 137 Chair, Board of Publications Trustees Members in the News . -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
A Role for Sigma Receptors in Stimulant Self Administration and Addiction
Pharmaceuticals 2011, 4, 880-914; doi:10.3390/ph4060880 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review A Role for Sigma Receptors in Stimulant Self Administration and Addiction Jonathan L. Katz *, Tsung-Ping Su, Takato Hiranita, Teruo Hayashi, Gianluigi Tanda, Theresa Kopajtic and Shang-Yi Tsai Psychobiology and Cellular Pathobiology Sections, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, 21224, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]. Received: 16 May 2011; in revised form: 11 June 2011 / Accepted: 13 June 2011 / Published: 17 June 2011 Abstract: Sigma1 receptors (σ1Rs) represent a structurally unique class of intracellular proteins that function as chaperones. σ1Rs translocate from the mitochondria-associated membrane to the cell nucleus or cell membrane, and through protein-protein interactions influence several targets, including ion channels, G-protein-coupled receptors, lipids, and other signaling proteins. Several studies have demonstrated that σR antagonists block stimulant-induced behavioral effects, including ambulatory activity, sensitization, and acute toxicities. Curiously, the effects of stimulants have been blocked by σR antagonists tested under place-conditioning but not self-administration procedures, indicating fundamental differences in the mechanisms underlying these two effects. The self administration of σR agonists has been found in subjects previously trained to self administer cocaine. The reinforcing effects of the σR agonists were blocked by σR antagonists. Additionally, σR agonists were found to increase dopamine concentrations in the nucleus accumbens shell, a brain region considered important for the reinforcing effects of abused drugs. -
Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors
1 Exploring the activity of an inhibitory neurosteroid at GABAA receptors Sandra Seljeset A thesis submitted to University College London for the Degree of Doctor of Philosophy November 2016 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street WC1E 6BT 2 Declaration I, Sandra Seljeset, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I can confirm that this has been indicated in the thesis. 3 Abstract The GABAA receptor is the main mediator of inhibitory neurotransmission in the central nervous system. Its activity is regulated by various endogenous molecules that act either by directly modulating the receptor or by affecting the presynaptic release of GABA. Neurosteroids are an important class of endogenous modulators, and can either potentiate or inhibit GABAA receptor function. Whereas the binding site and physiological roles of the potentiating neurosteroids are well characterised, less is known about the role of inhibitory neurosteroids in modulating GABAA receptors. Using hippocampal cultures and recombinant GABAA receptors expressed in HEK cells, the binding and functional profile of the inhibitory neurosteroid pregnenolone sulphate (PS) were studied using whole-cell patch-clamp recordings. In HEK cells, PS inhibited steady-state GABA currents more than peak currents. Receptor subtype selectivity was minimal, except that the ρ1 receptor was largely insensitive. PS showed state-dependence but little voltage-sensitivity and did not compete with the open-channel blocker picrotoxinin for binding, suggesting that the channel pore is an unlikely binding site. By using ρ1-α1/β2/γ2L receptor chimeras and point mutations, the binding site for PS was probed. -
(12) Patent Application Publication (10) Pub. No.: US 2003/0171347 A1 Matsumoto (43) Pub
US 2003.0171347A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0171347 A1 Matsumoto (43) Pub. Date: Sep. 11, 2003 (54) SIGMA RECEPTOR ANTAGONISTS HAVING Publication Classification ANT-COCANE PROPERTIES AND USES THEREOF (51) Int. Cl." ......................... A61K 31/55; A61K 31/33; A61K 31/397; A61K 31/445; (76) Inventor: Rae R. Matsumoto, Edmond, OK (US) A61K 31/40; A61K 31/137 (52) U.S. Cl. .............. 514/183; 514/210.01; 514/217.12; Correspondence Address: 514/317; 514/408; 514/649 DUNLAP, CODDING & ROGERS PC. PO BOX 16370 OKLAHOMA CITY, OK 73114 (US) (57) ABSTRACT (21) Appl. No.: 10/178,859 The present invention relates to novel Sigma receptor antagonist compounds that have anti-cocaine properties. (22) Filed: Jun. 21, 2002 These Sigma receptor antagonists are useful in the treatment Related U.S. Application Data of cocaine overdose and addiction as well as movement disorders. The Sigma receptor antagonists of the present (63) Continuation of application No. 09/715,911, filed on invention may also be used in the treatment of neurological, Nov. 17, 2000, now abandoned, which is a continu psychiatric, gastrointestinal, cardiovascular, endocrine and ation of application No. 09/316,877, filed on May 21, immune System disorders as well as for imaging procedures. 1999, now abandoned. The present invention also relates to novel pharmaceutical compounds incorporating Sigma receptor antagonists which (60) Provisional application No. 60/086,550, filed on May can be used to treat overdose and addiction resulting from 21, 1998. the use of cocaine and/or other drugs of abuse. -
PR6 2008.Vp:Corelventura
Pharmacological Reports Copyright © 2008 2008, 60, 889–895 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Effects of selective s receptor ligands on glucocorticoid receptor-mediated gene transcription in LMCAT cells Gra¿yna Skuza1, Zofia Rogó¿1, Magdalena Szymañska2, Bogus³awa Budziszewska2 1Department of Pharmacology, 2Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Smêtna 12, PL 31-343 Kraków, Poland Correspondence: Gra¿yna Skuza, e-mail: [email protected] Abstract: It has been shown previously that s receptor agonists reveal potential antidepressant activity in experimental models. Moreover, some data indicate s receptor contribution to stress-induced responses (e.g., conditioned fear stress in mice), though the mechanism by which s ligands can exert their effects, remains unclear. Recent studies have indicated that antidepressant drugs (ADs) inhibit glu- cocorticoid receptor (GR) function in vitro. The aim of the present study was to find out whether s receptor ligands are able to di- rectly affect GR action. To this end, we evaluated the effect of s receptor agonists and antagonists on GR function in mouse fibroblast cells (L929) stably transfected with mouse mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) plas- mid (LMCAT cells). For this study, we chose SA 4503, PRE 084, DTG (selective s1 or s1/2 receptor agonists) and BD 1047, SM 21, rimcazole (s receptor antagonists). Fluvoxamine, the selective serotonin reuptake inhibitor with s1/2 receptor affinity, was used for comparison. It was found that SM 21 (at 1, 3, 10 and 30 mM), BD 1047 (3, 10 and 30 mM) rimcazole (10 mM), and fluvoxamine (at 3, 10 and 30 mM) significantly inhibited corticosterone-induced gene transcription, while DTG, SA 4503 and PRE 084 remained inef- fective. -
Stems for Nonproprietary Drug Names
USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol -
Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Changes to Astrocyte Structure and Function" (2020)
University of Kentucky UKnowledge Theses and Dissertations--Medical Sciences Medical Sciences 2020 Involvement of the Sigma-1 Receptor in Methamphetamine- Mediated Changes to Astrocyte Structure and Function Richik Neogi University of Kentucky, [email protected] Author ORCID Identifier: https://orcid.org/0000-0002-8716-8812 Digital Object Identifier: https://doi.org/10.13023/etd.2020.363 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Neogi, Richik, "Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Changes to Astrocyte Structure and Function" (2020). Theses and Dissertations--Medical Sciences. 12. https://uknowledge.uky.edu/medsci_etds/12 This Master's Thesis is brought to you for free and open access by the Medical Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Medical Sciences by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. -
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
Sigma-1 Receptor Engages an Anti-Inflammatory and Antioxidant
antioxidants Article Sigma-1 Receptor Engages an Anti-Inflammatory and Antioxidant Feedback Loop Mediated by Peroxiredoxin in Experimental Colitis Nikoletta Almási 1, Szilvia Török 1, Zsuzsanna Valkusz 2,Máté Tajti 2, Ákos Csonka 3, Zsolt Murlasits 4, Anikó Pósa 1,5, Csaba Varga 1 and Krisztina Kupai 1,2,* 1 Department of Physiology, Anatomy and Neuroscience, University of Szeged, H-6726 Szeged, Hungary; [email protected] (N.A.); [email protected] (S.T.); [email protected] (A.P.); [email protected] (C.V.) 2 Department of Medicine, Medical Faculty, Albert Szent-Györgyi Clinical Center, University of Szeged, H-6720 Szeged, Hungary; [email protected] (Z.V.); [email protected] (M.T.) 3 Department of Traumatology, University of Szeged, H-6725 Szeged, Hungary; [email protected] 4 Laboratory Animals Research Center, Qatar University, Doha 2713, Qatar; [email protected] 5 Interdisciplinary Excellence Center, University of Szeged, H-6726 Szeged, Hungary * Correspondence: [email protected]; Tel.: +36-6254-4884 Received: 9 October 2020; Accepted: 2 November 2020; Published: 4 November 2020 Abstract: Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory condition of the gastrointestinal tract. Since the treatment of IBD is still an unresolved issue, we designed our study to investigate the effect of a novel therapeutic target, sigma-1 receptor (σ1R), considering its ability to activate antioxidant molecules. As a model, 2,4,6-trinitrobenzenesulfonic acid (TNBS) was used to induce colitis in Wistar–Harlan male rats. -
N,N-Dimethyltryptamine Compound Found in the Hallucinogenic Tea Ayahuasca, Regulates Adult Neurogenesis in Vitro and in Vivo Jose A
Morales-Garcia et al. Translational Psychiatry (2020) 10:331 https://doi.org/10.1038/s41398-020-01011-0 Translational Psychiatry ARTICLE Open Access N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo Jose A. Morales-Garcia 1,2,3,4, Javier Calleja-Conde 5, Jose A. Lopez-Moreno 5, Sandra Alonso-Gil1,2, Marina Sanz-SanCristobal1,2, Jordi Riba6 and Ana Perez-Castillo 1,2,4 Abstract N,N-dimethyltryptamine (DMT) is a component of the ayahuasca brew traditionally used for ritual and therapeutic purposes across several South American countries. Here, we have examined, in vitro and vivo, the potential neurogenic effect of DMT. Our results demonstrate that DMT administration activates the main adult neurogenic niche, the subgranular zone of the dentate gyrus of the hippocampus, promoting newly generated neurons in the granular zone. Moreover, these mice performed better, compared to control non-treated animals, in memory tests, which suggest a functional relevance for the DMT-induced new production of neurons in the hippocampus. Interestingly, the neurogenic effect of DMT appears to involve signaling via sigma-1 receptor (S1R) activation since S1R antagonist blocked the neurogenic effect. Taken together, our results demonstrate that DMT treatment activates the subgranular neurogenic niche regulating the proliferation of neural stem cells, the migration of neuroblasts, and promoting the generation of new neurons in the hippocampus, therefore enhancing adult neurogenesis and